Why Did Sprouts Stock Fall So Much?
Shares of health-oriented grocery chain Sprouts Farmers Market (NASDAQ:SFM) have…
Sell
36
ZLAB Quote, Financials, Valuation and Earnings
Last price:
$21.93
Seasonality move
:
28.4%
Day range:
$21.68 - $24.44
52-week range:
$23.82 - $44.34
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
6.05x
P/B ratio:
3.49x
Volume:
1.2M
Avg. volume:
774.4K
1-year change:
-23.6%
Market cap:
$2.8B
Revenue:
$399.2M
EPS (TTM):
-$2.00
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ZLAB
Zai Lab Ltd.
|
$143.7M | -$0.29 | 70.32% | -83.6% | $55.15 |
|
CASI
CASI Pharmaceuticals, Inc.
|
-- | -- | -100% | -- | $4.00 |
|
CCM
Concord Medical Services Holdings Ltd.
|
-- | -- | -- | -- | -- |
|
CPHI
China Pharma Holdings, Inc.
|
-- | -- | -- | -- | -- |
|
RDY
Dr. Reddy's Laboratories Ltd.
|
$983.7M | $0.19 | -2.63% | 3.83% | $14.98 |
|
SVA
Sinovac Biotech Ltd.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ZLAB
Zai Lab Ltd.
|
$24.80 | $55.15 | $2.8B | -- | $0.00 | 0% | 6.05x |
|
CASI
CASI Pharmaceuticals, Inc.
|
$1.33 | $4.00 | $20.6M | -- | $0.00 | 0% | 0.65x |
|
CCM
Concord Medical Services Holdings Ltd.
|
$5.57 | -- | $24.2M | -- | $0.00 | 0% | 0.48x |
|
CPHI
China Pharma Holdings, Inc.
|
$1.61 | -- | $5.2M | -- | $0.00 | 0% | 2.42x |
|
RDY
Dr. Reddy's Laboratories Ltd.
|
$13.47 | $14.98 | $11.2B | 16.49x | $0.09 | 0.69% | 2.83x |
|
SVA
Sinovac Biotech Ltd.
|
$6.47 | -- | $464.9M | -- | $55.00 | 0% | 1.50x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ZLAB
Zai Lab Ltd.
|
19.47% | -0.283 | 4.98% | 2.81x |
|
CASI
CASI Pharmaceuticals, Inc.
|
-1188.71% | -1.101 | 102.48% | 0.32x |
|
CCM
Concord Medical Services Holdings Ltd.
|
273.84% | -2.733 | 77.28% | 0.19x |
|
CPHI
China Pharma Holdings, Inc.
|
34.03% | -2.231 | 58.67% | 2.77x |
|
RDY
Dr. Reddy's Laboratories Ltd.
|
14.04% | -0.488 | 5.65% | 1.12x |
|
SVA
Sinovac Biotech Ltd.
|
3.46% | 3.336 | 12.91% | 11.22x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ZLAB
Zai Lab Ltd.
|
$67M | -$55.1M | -23.28% | -27.83% | -49.92% | -$35.6M |
|
CASI
CASI Pharmaceuticals, Inc.
|
$2.1M | -$10.7M | -240.99% | -70405.41% | -256.53% | -- |
|
CCM
Concord Medical Services Holdings Ltd.
|
-- | -- | -7.49% | -19.78% | -- | -- |
|
CPHI
China Pharma Holdings, Inc.
|
-$244.4K | -$652.1K | -33.7% | -51.27% | -63.57% | $281.2K |
|
RDY
Dr. Reddy's Laboratories Ltd.
|
$517.5M | $178.5M | 14.9% | 17.11% | 17.71% | $49.2M |
|
SVA
Sinovac Biotech Ltd.
|
-- | -- | -1.02% | -1.05% | -- | -- |
Zai Lab Ltd. vs. Competitors
-
Which has Higher Returns ZLAB or CASI?
CASI Pharmaceuticals, Inc. has a net margin of -37.03% compared to Zai Lab Ltd.'s net margin of -320.36%. Zai Lab Ltd.'s return on equity of -27.83% beat CASI Pharmaceuticals, Inc.'s return on equity of -70405.41%.
Company Gross Margin Earnings Per Share Invested Capital ZLABZai Lab Ltd.60.7% -$0.40 $983.2M CASICASI Pharmaceuticals, Inc.49.29% -$0.86 -$1.6M -
What do Analysts Say About ZLAB or CASI?
Zai Lab Ltd. has a consensus price target of $55.15, signalling upside risk potential of 122.39%. On the other hand CASI Pharmaceuticals, Inc. has an analysts' consensus of $4.00 which suggests that it could grow by 200.75%. Given that CASI Pharmaceuticals, Inc. has higher upside potential than Zai Lab Ltd., analysts believe CASI Pharmaceuticals, Inc. is more attractive than Zai Lab Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ZLABZai Lab Ltd.8 1 0 CASICASI Pharmaceuticals, Inc.0 0 0 -
Is ZLAB or CASI More Risky?
Zai Lab Ltd. has a beta of 1.068, which suggesting that the stock is 6.781% more volatile than S&P 500. In comparison CASI Pharmaceuticals, Inc. has a beta of 0.824, suggesting its less volatile than the S&P 500 by 17.552%.
-
Which is a Better Dividend Stock ZLAB or CASI?
Zai Lab Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CASI Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zai Lab Ltd. pays -- of its earnings as a dividend. CASI Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ZLAB or CASI?
Zai Lab Ltd. quarterly revenues are $110.4M, which are larger than CASI Pharmaceuticals, Inc. quarterly revenues of $4.2M. Zai Lab Ltd.'s net income of -$40.9M is lower than CASI Pharmaceuticals, Inc.'s net income of -$13.4M. Notably, Zai Lab Ltd.'s price-to-earnings ratio is -- while CASI Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zai Lab Ltd. is 6.05x versus 0.65x for CASI Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ZLABZai Lab Ltd.6.05x -- $110.4M -$40.9M CASICASI Pharmaceuticals, Inc.0.65x -- $4.2M -$13.4M
-
Which has Higher Returns ZLAB or CCM?
Concord Medical Services Holdings Ltd. has a net margin of -37.03% compared to Zai Lab Ltd.'s net margin of --. Zai Lab Ltd.'s return on equity of -27.83% beat Concord Medical Services Holdings Ltd.'s return on equity of -19.78%.
Company Gross Margin Earnings Per Share Invested Capital ZLABZai Lab Ltd.60.7% -$0.40 $983.2M CCMConcord Medical Services Holdings Ltd.-- -- $727.8M -
What do Analysts Say About ZLAB or CCM?
Zai Lab Ltd. has a consensus price target of $55.15, signalling upside risk potential of 122.39%. On the other hand Concord Medical Services Holdings Ltd. has an analysts' consensus of -- which suggests that it could grow by 115.44%. Given that Zai Lab Ltd. has higher upside potential than Concord Medical Services Holdings Ltd., analysts believe Zai Lab Ltd. is more attractive than Concord Medical Services Holdings Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ZLABZai Lab Ltd.8 1 0 CCMConcord Medical Services Holdings Ltd.0 0 0 -
Is ZLAB or CCM More Risky?
Zai Lab Ltd. has a beta of 1.068, which suggesting that the stock is 6.781% more volatile than S&P 500. In comparison Concord Medical Services Holdings Ltd. has a beta of -1.087, suggesting its less volatile than the S&P 500 by 208.704%.
-
Which is a Better Dividend Stock ZLAB or CCM?
Zai Lab Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Concord Medical Services Holdings Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zai Lab Ltd. pays -- of its earnings as a dividend. Concord Medical Services Holdings Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ZLAB or CCM?
Zai Lab Ltd. quarterly revenues are $110.4M, which are larger than Concord Medical Services Holdings Ltd. quarterly revenues of --. Zai Lab Ltd.'s net income of -$40.9M is higher than Concord Medical Services Holdings Ltd.'s net income of --. Notably, Zai Lab Ltd.'s price-to-earnings ratio is -- while Concord Medical Services Holdings Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zai Lab Ltd. is 6.05x versus 0.48x for Concord Medical Services Holdings Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ZLABZai Lab Ltd.6.05x -- $110.4M -$40.9M CCMConcord Medical Services Holdings Ltd.0.48x -- -- --
-
Which has Higher Returns ZLAB or CPHI?
China Pharma Holdings, Inc. has a net margin of -37.03% compared to Zai Lab Ltd.'s net margin of -51.51%. Zai Lab Ltd.'s return on equity of -27.83% beat China Pharma Holdings, Inc.'s return on equity of -51.27%.
Company Gross Margin Earnings Per Share Invested Capital ZLABZai Lab Ltd.60.7% -$0.40 $983.2M CPHIChina Pharma Holdings, Inc.-23.83% -$0.16 $10.1M -
What do Analysts Say About ZLAB or CPHI?
Zai Lab Ltd. has a consensus price target of $55.15, signalling upside risk potential of 122.39%. On the other hand China Pharma Holdings, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Zai Lab Ltd. has higher upside potential than China Pharma Holdings, Inc., analysts believe Zai Lab Ltd. is more attractive than China Pharma Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ZLABZai Lab Ltd.8 1 0 CPHIChina Pharma Holdings, Inc.0 0 0 -
Is ZLAB or CPHI More Risky?
Zai Lab Ltd. has a beta of 1.068, which suggesting that the stock is 6.781% more volatile than S&P 500. In comparison China Pharma Holdings, Inc. has a beta of 1.093, suggesting its more volatile than the S&P 500 by 9.347%.
-
Which is a Better Dividend Stock ZLAB or CPHI?
Zai Lab Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. China Pharma Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zai Lab Ltd. pays -- of its earnings as a dividend. China Pharma Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ZLAB or CPHI?
Zai Lab Ltd. quarterly revenues are $110.4M, which are larger than China Pharma Holdings, Inc. quarterly revenues of $1M. Zai Lab Ltd.'s net income of -$40.9M is lower than China Pharma Holdings, Inc.'s net income of -$528.4K. Notably, Zai Lab Ltd.'s price-to-earnings ratio is -- while China Pharma Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zai Lab Ltd. is 6.05x versus 2.42x for China Pharma Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ZLABZai Lab Ltd.6.05x -- $110.4M -$40.9M CPHIChina Pharma Holdings, Inc.2.42x -- $1M -$528.4K
-
Which has Higher Returns ZLAB or RDY?
Dr. Reddy's Laboratories Ltd. has a net margin of -37.03% compared to Zai Lab Ltd.'s net margin of 16.2%. Zai Lab Ltd.'s return on equity of -27.83% beat Dr. Reddy's Laboratories Ltd.'s return on equity of 17.11%.
Company Gross Margin Earnings Per Share Invested Capital ZLABZai Lab Ltd.60.7% -$0.40 $983.2M RDYDr. Reddy's Laboratories Ltd.51.32% $0.20 $4.7B -
What do Analysts Say About ZLAB or RDY?
Zai Lab Ltd. has a consensus price target of $55.15, signalling upside risk potential of 122.39%. On the other hand Dr. Reddy's Laboratories Ltd. has an analysts' consensus of $14.98 which suggests that it could grow by 11.23%. Given that Zai Lab Ltd. has higher upside potential than Dr. Reddy's Laboratories Ltd., analysts believe Zai Lab Ltd. is more attractive than Dr. Reddy's Laboratories Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ZLABZai Lab Ltd.8 1 0 RDYDr. Reddy's Laboratories Ltd.2 2 1 -
Is ZLAB or RDY More Risky?
Zai Lab Ltd. has a beta of 1.068, which suggesting that the stock is 6.781% more volatile than S&P 500. In comparison Dr. Reddy's Laboratories Ltd. has a beta of 0.374, suggesting its less volatile than the S&P 500 by 62.637%.
-
Which is a Better Dividend Stock ZLAB or RDY?
Zai Lab Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Dr. Reddy's Laboratories Ltd. offers a yield of 0.69% to investors and pays a quarterly dividend of $0.09 per share. Zai Lab Ltd. pays -- of its earnings as a dividend. Dr. Reddy's Laboratories Ltd. pays out 8.91% of its earnings as a dividend. Dr. Reddy's Laboratories Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ZLAB or RDY?
Zai Lab Ltd. quarterly revenues are $110.4M, which are smaller than Dr. Reddy's Laboratories Ltd. quarterly revenues of $1B. Zai Lab Ltd.'s net income of -$40.9M is lower than Dr. Reddy's Laboratories Ltd.'s net income of $163.4M. Notably, Zai Lab Ltd.'s price-to-earnings ratio is -- while Dr. Reddy's Laboratories Ltd.'s PE ratio is 16.49x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zai Lab Ltd. is 6.05x versus 2.83x for Dr. Reddy's Laboratories Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ZLABZai Lab Ltd.6.05x -- $110.4M -$40.9M RDYDr. Reddy's Laboratories Ltd.2.83x 16.49x $1B $163.4M
-
Which has Higher Returns ZLAB or SVA?
Sinovac Biotech Ltd. has a net margin of -37.03% compared to Zai Lab Ltd.'s net margin of --. Zai Lab Ltd.'s return on equity of -27.83% beat Sinovac Biotech Ltd.'s return on equity of -1.05%.
Company Gross Margin Earnings Per Share Invested Capital ZLABZai Lab Ltd.60.7% -$0.40 $983.2M SVASinovac Biotech Ltd.-- -- $11.8B -
What do Analysts Say About ZLAB or SVA?
Zai Lab Ltd. has a consensus price target of $55.15, signalling upside risk potential of 122.39%. On the other hand Sinovac Biotech Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Zai Lab Ltd. has higher upside potential than Sinovac Biotech Ltd., analysts believe Zai Lab Ltd. is more attractive than Sinovac Biotech Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ZLABZai Lab Ltd.8 1 0 SVASinovac Biotech Ltd.0 0 0 -
Is ZLAB or SVA More Risky?
Zai Lab Ltd. has a beta of 1.068, which suggesting that the stock is 6.781% more volatile than S&P 500. In comparison Sinovac Biotech Ltd. has a beta of 0.544, suggesting its less volatile than the S&P 500 by 45.554%.
-
Which is a Better Dividend Stock ZLAB or SVA?
Zai Lab Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sinovac Biotech Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $55.00 per share. Zai Lab Ltd. pays -- of its earnings as a dividend. Sinovac Biotech Ltd. pays out -328.35% of its earnings as a dividend.
-
Which has Better Financial Ratios ZLAB or SVA?
Zai Lab Ltd. quarterly revenues are $110.4M, which are larger than Sinovac Biotech Ltd. quarterly revenues of --. Zai Lab Ltd.'s net income of -$40.9M is higher than Sinovac Biotech Ltd.'s net income of --. Notably, Zai Lab Ltd.'s price-to-earnings ratio is -- while Sinovac Biotech Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zai Lab Ltd. is 6.05x versus 1.50x for Sinovac Biotech Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ZLABZai Lab Ltd.6.05x -- $110.4M -$40.9M SVASinovac Biotech Ltd.1.50x -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Amazon Go Up So Much?
Shares of Amazon (NASDAQ:AMZN) soared late last week, bringing the…
Why Did Leonardo DRS Stock Go Down?
Leonardo DRS (NASDAQ:DRS) is a diversified defense manufacturing business that…
Stock Ideas
Sell
49
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
62
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Sell
43
Is MSFT Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 36x
Alerts
Buy
65
FRGE alert for Nov 7
Forge Global Holdings, Inc. [FRGE] is down 0.18% over the past day.
Sell
45
AMSC alert for Nov 7
American Superconductor Corp. [AMSC] is up 6.32% over the past day.
Sell
17
ELF alert for Nov 7
e.l.f. Beauty, Inc. [ELF] is down 3.66% over the past day.
